ARTICLE | Clinical News
Isis Pharmaceuticals regulatory update
April 10, 1995 7:00 AM UTC
Isis Pharmaceuticals (ISIP) ISIP received notice of allowance for two U.S. patents covering two antisense compounds. ISIS 2922, a selective inhibitor of cytomegalovirus (CMV), is in Phase III trials ...